Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Acquired by Kennondale Capital Management LLC

Kennondale Capital Management LLC increased its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 50.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 202,743 shares of the company's stock after acquiring an additional 68,298 shares during the period. Kennondale Capital Management LLC owned approximately 0.23% of Amylyx Pharmaceuticals worth $718,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Valeo Financial Advisors LLC purchased a new stake in Amylyx Pharmaceuticals during the 1st quarter valued at $35,000. Fox Run Management L.L.C. bought a new position in shares of Amylyx Pharmaceuticals in the 4th quarter worth about $45,000. Alpine Global Management LLC bought a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at about $45,000. RPO LLC bought a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at about $46,000. Finally, EntryPoint Capital LLC bought a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at about $53,000. Hedge funds and other institutional investors own 95.84% of the company's stock.

Amylyx Pharmaceuticals Trading Down 2.3%

AMLX traded down $0.19 on Friday, hitting $8.11. 142,365 shares of the company's stock were exchanged, compared to its average volume of 1,111,933. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.76 and a fifty-two week high of $8.72. The firm has a 50-day moving average price of $6.18 and a 200-day moving average price of $4.63. The stock has a market cap of $722.93 million, a price-to-earnings ratio of -2.61 and a beta of -0.49.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.03. On average, equities analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Analyst Ratings Changes

AMLX has been the subject of a number of research analyst reports. Mizuho lifted their price target on shares of Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a research note on Wednesday, May 14th. Leerink Partnrs upgraded shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. The Goldman Sachs Group raised shares of Amylyx Pharmaceuticals to a "buy" rating and set a $10.00 target price on the stock in a report on Thursday, July 10th. UBS Group raised shares of Amylyx Pharmaceuticals to a "hold" rating in a report on Tuesday, June 24th. Finally, Citigroup began coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday, June 17th. They set a "buy" rating and a $12.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $11.75.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.